Freeze-All Policy: Is It Right for Everyone?

Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD

The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Pavani Chalasani, MD, MPH

Acquired ESR1 mutations cannot be detected on archival tissue and require liquid biopsy. Fortunately, this approach circumvents the challenges of acquiring serial tissue while allowing for the real-time monitoring of ESR1 status in patients with metastatic breast cancer. Learn more about the rationale behind liquid biopsies and best practices for utilizing them in clinical practice with Dr. Charles Turck and Dr. Pavani Chalasani, Division Director of Hematology-Oncology at the GW Cancer Center in Washington, DC.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stephanie Graff, MD
Guest: Pavani Chalasani, MD, MPH

When treating patients with metastatic breast cancer, it’s important to repeatedly conduct liquid biopsies to look for acquired ESR1 mutations when patients progress after endocrine therapy, even if initial testing was done. That’s why Dr. Charles Turck is breaking down best practices for utilizing liquid biopsies to detect ESR1 mutations with Drs. Stephanie Graff and Pavani Chalasani. Dr. Graff is the Director of Breast Oncology at the Lifespan Cancer Institute in Providence, Rhode Island, and Dr. Chalasani is the Division Director of Hematology-Oncology at the GW Cancer Center in Washington, DC.

Guest: Megan Kruse, MD

While intrinsic mutations, like PIK3CA, are present at the outset and can be identified upfront in patients with HR+/HER2- metastatic breast cancer, acquired mutations, like ESR1, cannot be detected on baseline tumor profiling. That’s why longitudinal monitoring with liquid biopsies over the course of treatment is required. Learn more about these key differences in testing for acquired versus intrinsic mutations with Dr. Megan Kruse, a breast medical oncologist at the Cleveland Clinic.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Oluwatosin Goje, MD

A delay in diagnosis and treatment of vulvovaginitis can have big impacts on a patient’s quality of life and their overall health. Explore how screening modalities like molecular tests and treatment guidelines from the CDC can help optimize the management of patients with vulvovaginitis with Dr. Charles Turck and Dr. Tosin Goje, Associate Professor of Obstetrics and Gynecology and Reproductive Biology at the Cleveland Clinic’s Lerner College of Medicine at Case Western Reserve University.

Guest: Oluwatosin Goje, MD

Better diagnostic techniques with rapid turnover and therapies for the treatment of both acute and chronic vulvovaginitis can help address the long-term burden facing reproductive-aged women. Learn more with Dr. Tosin Goje, Associate Professor of Obstetrics/Gynecology and Reproductive Biology at the Cleveland Clinic's Lerner College of Medicine at Case Western Reserve University.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Megan Kruse, MD

From disease-related factors to the latest clinical trial data, there’s a lot to consider when selecting a therapy for patients with ER+/HER2- metastatic breast cancer. Here with Dr. Charles Turck to break down the key factors that can guide our treatment selections is breast medical oncologist Dr. Megan Kruse from the Cleveland Clinic in Ohio.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO

The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.

Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD

This program is no longer available for credit.

Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.

Host: Hector O. Chapa, MD, FACOG
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Anum Minhas, MD, MHS

Cardiovascular disease is currently the leading cause of death for pregnant and postpartum women in the United States, and from a global perspective, hypertensive complications during pregnancy result in 50,000 maternal deaths each and every year. This, along with the increasing rates of peripartum cardiomyopathy diagnoses, is why a new subspeciality of cardiology is needed. So what exactly is cardio-obstetrics? To learn more about how this emerging subspecialty is helping to provide better care for our pregnant and postpartum patients, Dr. Hector Chapa speaks with Drs. Erin Michos and Anum Minhas.